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Background
Malignant pleural mesothelioma (MPM) remains a major
challenge, with limited therapeutic options. Multifocal
intrapleural disease can cause disabling symptoms of
pain and breathlessness, in the absence of distant metas-
tases, so an intrapleural treatment approach is attractive.
SEPREHVIR (HSV1716) is a mutant oncolytic herpes
simplex virus type 1 deleted in the gene encoding the
neurovirulence factor ICP34.5. Mutants lacking ICP34.5
are selectively replication competent in cancer cells and
induce anti-tumour immune responses. Clinical studies
with SEPREHVIR have been completed in adult glioma,
melanoma, H&NSCC, and studies are ongoing in both
pediatric CNS and non-CNS solid tumors and MPM. In
total, 92 patients have received SEPREHVIR via intratu-
moral, loco-regional, and intravenous administration and
it is well-tolerated with no shedding in patients.
SEPREHVIR selectivity for replication only in tumour
cells and intimations of efficacy and immuno-stimulatory
potential have been demonstrated.
Methods
A Phase I/IIa trial to determine the safety and potential for
efficacy of SEPREHVIR given intrapleurally to patients
with MPM is currently ongoing. Patients receive 1x107iu
SEPREHVIR through their pleural catheter on one, two or
four occasions a week apart, in three separate patient
cohorts. To date 9 patients have been treated, 3 in each
cohort and SEPREHVIR has been well-tolerated with few
adverse events in any patients. Pleural fluid and plasma
samples have been collected pre- and post treatment and
analysed to assess patient responses to SEPREHVIR
administration. Pleural fluids have been analysed by ELISA
for cytokines/chemokines and were rich in IL-6, IL-8, MIG
and VEGF.
Results
Robust Th1 responses with increased IFN-a, IP-10, MIG
and TNFa were observed in most patients after
SEPREHVIR administration with IL-2, IL-10 and IL-12
responses in patients receiving 4 doses. IL-1a, IL-4,
IL-21 and IFN-a were not detected pre-treatment and,
along with IL8, showed minimal responses to SEPREH-
VIR administration.
Analysis of plasma samples indicated strong anti-HSV
IgG responses post SEPREHVIR administration, particu-
larly after 2 and 4 doses and the presence of anti-HSV
IgG in pleural fluids. Despite this, HSV DNA was
detected in the pleural fluids of most patients and in
some persisted for at least two weeks post-administra-
tion. Interestingly, in most patients, there was a novel
anti-tumour IgG response as detected by immunoblot-
ting against extracts from MPM cell lines.
Conclusions
Thus, our trial demonstrates that oncolytic SEPREHVIR
has immunotherapeutic potential capable of inducing
novel anti-tumour immune responses in patients and
further studies are ongoing. This also confirms pre-clinical
studies that clearly demonstrated Seprehvir’s immunother-
apeutic mode of action.
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